Neurocrine Biosciences Inc (NBIX)
Neurocrine Biosciences develops and sells medicines for neurological, psychiatric and endocrine disorders, based in San Diego. It last closed at $165.92 on Nov 17, up 0.30% on the day. NBIX reports earnings on Wed, Feb 10, 2027. The average 12-month price target from 8 analysts is $206.13 (+24.2% from the last close), with a high of $253.00 and a low of $150.00. Analyst consensus is Strong Buy, based on the latest ratings from 8 firms (6 buy, 2 hold, 0 sell). Over the past 90 days StreetAlpha recorded 2 whale options trades in NBIX, 50% of them bullish and 50% bearish. In the past 30 days there were 3 dark pool prints totaling $2.0M, the largest $727K.
Key Stats
Last 12 monthsNot reported for this period.
From NBIX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 2). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 8 analysts who set a price target on NBIX in the past 90 days. The average target is $206.13, with a high of $253.00 and a low of $150.00, compared with the last close of $165.92.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 4 | Guggenheim | Target raised | Buy | $207 → $224 |
| Nov 3 | RBC Capital | Target lowered | Buy | $198 → $190 |
| Nov 3 | Canaccord Genuity | Target raised | Buy | $210 → $220 |
| Nov 3 | Piper Sandler | Target raised | Buy | $210 → $215 |
| Oct 12 | BMO Capital | Target lowered | Hold | $170 → $150 |
Technical Analysis
The stock is 5% above its 20 day and 10% above its 50 day average. It is 10% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 62). The nearest support is the Pivot at $164.72, and the nearest resistance the Pivot R1 at $167.45.
| RSI (14) | 61.98 | Strong, overbought above 70 | Neutral |
| MACD | 6.41 | Above its signal line | Bullish |
| Stochastic | 73.4 | Middle of its range | Neutral |
| ADX (14) | 33.3 | Trending up | |
| Williams %R | -28.0 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 49.1 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | +0.7% | Change over 10 sessions | Bullish |
| ATR (14) | $5.32 | Typical daily range, 3.2% of price |
| RSI (14) | 59.51 | Middle of its range | Neutral |
| MACD | 1.76 | Above its signal line | Bullish |
| Stochastic | 82.2 | Near the top of its range | Overbought |
| ADX (14) | 22.3 | Weak trend | |
| Williams %R | -20.4 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 58.7 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | +6.2% | Change over 10 sessions | Bullish |
| ATR (14) | $10.54 | Typical daily range, 6.3% of price |
What happened before
See how NBIX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How NBIX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.
Whale Options Flow
90DNo whale options trades in NBIX in the last 90 days.
Dark Pool
30DNBIX Institutional Ownership
Full report →- ●405 buying vs 363 selling
- ●Held by funds -0.5 pts
- ▼Funds holding -12
- ▲Superinvestors: 3 added, 1 cut
- ▼Put/call 0.03 to 0.05
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 770 | 782 | −1.5% |
| In funds' top 10 | 7 | 9 | −22.2% |
| Held by funds | 100.0% | 100.5% | −0.5 pts |
| New / increased | 101 / 304 | 145 / 320 | −12.9% |
| Reduced / sold out | 256 / 107 | 224 / 65 | +25.6% |
| Put/call ratio | 0.05 | 0.03 | +31.9% |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether NBIX is in one of them and how their past NBIX trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered NBIX in an article yet. Here's the latest on the wider market.
NBIX Congress Trades
All congress trades →| Person | Type | Amount | Traded | Filed | Delay |
|---|---|---|---|---|---|
| Lisa McClainR · MI | Sell (partial) | $1K – $15K | Jun 17, 2025 | Aug 13, 2025 | 57 d |
| Lisa McClainR · MI | Buy | $1K – $15K | Jun 11, 2025 | Aug 13, 2025 | 63 d |
| Michael McCaulR · TX | Sell | $15K – $50K | Nov 19, 2024 | Dec 16, 2024 | 27 d |
| Michael McCaulR · TX | Sell | $1K – $15K | Aug 26, 2024 | Sep 16, 2024 | 21 d |
| Michael McCaulR · TX | Sell | $1K – $15K | Aug 26, 2024 | Sep 16, 2024 | 21 d |
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Neurocrine Biosciences
Neurocrine Biosciences is a biopharmaceutical company based in San Diego, California. It discovers, develops and sells medicines for neurological, psychiatric, endocrine and immune disorders. Its main product, INGREZZA, treats tardive dyskinesia and chorea linked to Huntington's disease, and CRENESSITY treats congenital adrenal hyperplasia. In the United States, it sells through specialty pharmacies and distributors, and its sales teams focus on neurology, psychiatry, long-term care and rare diseases.
- Headquarters
- San Diego, CA
- Founded
- 1992
- Website
- neurocrine.com ↗








